Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA4 | P22748 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900236 | 1.00 | REN (0.42) | RENBRD4L3MBTL1CA1CA2 | |
| SCHEMBL3914641 | 0.85 | TSHR (0.38) | RENLMNAKMT2A | |
| SCHEMBL21315834 | 0.85 | TSHR (0.38) | RENLMNAKMT2A | |
| SCHEMBL21315838 | 0.85 | TSHR (0.38) | RENLMNAKMT2A | |
| SCHEMBL17062858 | 0.81 | NR1H2 (0.40) | RENBRD4KMT2A | |
| SCHEMBL656518 | 0.81 | NR1H2 (0.40) | RENBRD4KMT2A | |
| SCHEMBL6628364 | 0.81 | NR1H2 (0.40) | RENBRD4KMT2A | |
| SCHEMBL2921471 | 0.81 | BRD4 (0.44) | RENBRD4L3MBTL1KDM4EKMT2A | |
| SCHEMBL16195811 | 0.81 | REN (0.40) | RENCA1CA2CA4CA9 | |
| SCHEMBL19133692 | 0.81 | REN (0.40) | RENCA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052528-A1 | TASPASE1 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-02-16 | — | — | US | disclosed |
| WO-2021102359-A2 | TASPASE1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| EP-3538091-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052528-A1 | TASPASE1 INHIBITORS AND USES THEREOF | RNASE1, TASP1, TPP1 | REN 3711/4885BRD4 2070/4885L3MBTL1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.